A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which there is no effective
treatment. Interferon-gamma is a medication that has been used for other lung diseases to
decrease scarring and fibrosis. Studies of interferon-gamma injected under the skin did not
show any improvement in survival in patients with IPF. We hypothesize that giving
interferon-gamma as a nebulized mist directly into the lungs can affect the immune system in
a way that decreases fibrosis.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
National Center for Research Resources (NCRR) Philips Respironics Stony Brook University